For Research Use Only. Not for human consumption. The following summarizes published preclinical/clinical literature for laboratory research purposes only. Not a substitute for or alternative to any approved medication.
What It Is
MOTS-c (Mitochondrial Open reading frame of the Twelve S rRNA type-c) is a 16-amino-acid mitochondrial-derived peptide (MDP), encoded not by nuclear DNA but by a short open reading frame within the mitochondrial 12S rRNA gene region. It was first characterized by Lee et al., who identified MOTS-c as a regulator of insulin sensitivity and metabolic homeostasis, joining humanin as one of the first recognized members of the MDP family Lee et al., Cell Metabolism, 2015. MOTS-c is studied in the literature as a stress-inducible signaling peptide capable of nuclear translocation, distinguishing it mechanistically from classical mitochondrial proteins Kim et al., Cell Metabolism, 2018.
Summary of Published Research Findings
In the original characterization study, MOTS-c administration in diet-induced obese mice was reported to attenuate age-dependent body-mass increase and to improve measures of insulin sensitivity in that model, with skeletal muscle identified as a primary target tissue Lee et al., Cell Metabolism, 2015.
Mechanistic nuclear-translocation research by Kim et al. demonstrated that under metabolic stress conditions, MOTS-c moves from the cytoplasm to the nucleus in cultured cells, where it regulates adaptive nuclear gene expression programs including antioxidant response pathways Kim et al., Cell Metabolism, 2018. Aging and physical performance research conducted in mice found that MOTS-c administration significantly enhanced physical performance across young, middle-aged, and old cohorts, and that endogenous MOTS-c is induced by exercise Reynolds et al., Nature Communications, 2021. A related human observational study reported that skeletal muscle MOTS-c expression was associated with myofiber composition in aging men, while circulating plasma MOTS-c levels declined with age Woodhead et al., Aging, 2020.
Cardiovascular disease models have also been used to study MOTS-c. Shen et al. reported that MOTS-c prevented development of heart failure under pressure-overload conditions in mice Shen et al., Journal of Cellular and Molecular Medicine, 2022. A separate diabetic rat model study reported that MOTS-c administration was associated with reduced myocardial damage markers via modulation of the CCN1/ERK1/2/EGR1 signaling pathway Wang et al., Frontiers in Nutrition, 2023, and a lipopolysaccharide-induced septic cardiomyopathy model reported protective associations attributed to AMPK-dependent signaling He et al., Acta Biochimica et Biophysica Sinica, 2023. A 2024 mechanistic study additionally reported that MOTS-c participates in plasma membrane repair processes by facilitating TRIM72 translocation in cell and animal injury models Zhang et al., Theranostics, 2024.
Proposed Mechanism of Action
The mechanism most consistently reported in the literature centers on activation of AMP-activated protein kinase (AMPK) signaling. Lee et al. proposed that MOTS-c inhibits the folate cycle and its downstream de novo purine biosynthesis pathway, which shifts cellular AMP/ATP ratios and activates AMPK, a key regulator of cellular energy sensing and glucose uptake Lee et al., Cell Metabolism, 2015. Under stress conditions, MOTS-c has also been reported to translocate to the nucleus and interact with stress-response transcription factors such as NRF2, driving expression of antioxidant response genes — a mechanism proposed to link mitochondrial signaling directly to nuclear gene regulation Kim et al., Cell Metabolism, 2018.
Research Use Only / Handling Note
MOTS-c 40mg is intended exclusively for in vitro and animal-model laboratory research, such as studies of AMPK signaling, skeletal muscle metabolism, or mitochondrial-nuclear communication. It is not intended for human or animal consumption, therapeutic administration, or diagnostic use.